A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes
Author:
Affiliation:
1. Pfizer Worldwide Research and Development Cambridge Massachusetts USA
2. Early Clinical Development Pfizer Inc Cambridge Massachusetts USA
3. Early Clinical Development Pfizer Inc Cambridge UK
Funder
Pfizer
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14946
Reference32 articles.
1. World Gastroenterology Organisation Global Guidelines
2. Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
3. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes
4. Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
5. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches;International Journal of Molecular Sciences;2024-08-10
2. New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease;Cell & Bioscience;2024-07-06
3. Metabolic reprogramming in liver fibrosis;Cell Metabolism;2024-07
4. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-11
5. Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells;Experimental Cell Research;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3